Clinical Trial Detail

NCT ID NCT03586609
Title Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Participants With Patients Previously Untreated Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Azacitidine + Cladribine + Cytarabine + Venetoclax

Age Groups: adult senior

No variant requirements are available.